UFP Technologies delivered first-quarter results that exceeded Wall Street’s expectations, with management citing strong momentum across its medical business as a primary driver. CEO Jeff Bailly explained that growth was led by the safe patient handling segment, which benefited from both new market share wins and elevated demand, following the acquisition of AJR. Other medical sub-segments like interventional and surgical infection prevention, orthopedics, and advanced wound care also posted notable growth, supported by the fading of inventory destocking trends. Management highlighted that recent acquisitions contributed significantly to revenue, with successful integration and cross-selling accelerating performance.
Is now the time to buy UFPT? Find out in our full research report (it’s free).
UFP Technologies (UFPT) Q1 CY2025 Highlights:
- Revenue: $148.1 million vs analyst estimates of $139.9 million (41.1% year-on-year growth, 5.9% beat)
- Adjusted EPS: $2.47 vs analyst estimates of $2.01 (22.9% beat)
- Adjusted EBITDA: $30.24 million vs analyst estimates of $28.26 million (20.4% margin, 7% beat)
- Operating Margin: 15.8%, in line with the same quarter last year
- Market Capitalization: $1.9 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions UFP Technologies’s Q1 Earnings Call
- Jaeson Schmidt (Lake Street) asked about share dynamics with the largest robotic surgery customer. CEO Jeff Bailly explained UFP Technologies currently holds about two-thirds share and expects to remain a core supplier due to a two-supplier mandate.
- Brett Fishbin (KeyBanc) sought details on strong growth in non-robotic medical segments. Bailly cited new product launches, fading destocking headwinds, and acquisition synergies as key drivers.
- Justin Ages (CJS) inquired about tariff impacts on competitors. Bailly responded that competitors in China are most affected, giving UFP Technologies an edge in certain segments, but anticipated only limited immediate benefit.
- Andrew Cooper (Raymond James) probed the effect of price reductions from transferring safe patient handling programs to the Dominican Republic. Bailly clarified that while revenue per unit may decrease, increased efficiencies should boost margins and overall profitability.
- Andrew Cooper (Raymond James) also asked about potential international expansion. Bailly indicated future growth may include Asia-Pacific, particularly if driven by customer demand, and noted ongoing expansion in Ireland and the Dominican Republic.
Catalysts in Upcoming Quarters
In the coming quarters, our team will closely monitor (1) the ramp-up of new robotic surgery programs and the scaling of safe patient handling capacity, (2) the pace of acquisition activity and integration outcomes, and (3) progress in operational efficiency from facility expansions in the Dominican Republic and Ireland. We will also watch for any material changes in tariff exposure or customer inventory trends.
UFP Technologies currently trades at $247.33, up from $197.16 just before the earnings. In the wake of this quarter, is it a buy or sell? The answer lies in our full research report (it’s free).
The Best Stocks for High-Quality Investors
Donald Trump’s victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs.
While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.
